Document:

Translation of Letter of Approval from the Office of the Chief Scientist

 Translation of 2010 Letter of Approval 

 
 Exhibit 10.34 

State of Israel 

Ministry of Trade and Industry 

Industrial Research and Development Administration 

Office of Chief Scientist 

Jerusalem                     

 Letter of Approval Number: 42678 

(Fiscal regulation: 38020101) 

Group: 13 
 To 

Nilimedix Ltd. 
 3 Ha’sadna 

Tirat Ha’Carmel 39032 

Letter of Approval 
  

	 	1.	We hereby inform you that the research committee, by virtue of its authority according to Article 17 of the Law for the Encouragement of Research and Development in the
Industry, 1984 (hereinafter: the “R&D Law”), has resolved in its meeting on 17/02/2010 to approve the program as submitted by you on 31/10/2009, which subject matter is: 

 

	 	a.	Subject of approved program: Advanced Passive Insulin Pump 

  

	 	b.	Performing the approved program: Nilimedix Ltd.  

Registration Number: 513229708 

(hereinafter – the “Approved Program”) 
  

	 	2.	a. The research and development expenses approved for the performance of the approved program will be in an amount of up to: NIS 5,980,378.

 In words: Five Million Nine Hundred Eighty Thousand Three Hundred and Seventy Eight NIS. 

 

	 	 	b. The rate of grant approved is 40% of the development expenses (addition with respect to a national priority zone A/ line of confrontation), which is up to an
amount of NIS 2,392,151. 

 In words: Two Million Three Hundred Ninety Two Thousand One Hundred and Fifty
One NIS. 
  

	 	3.	The approval is conditioned upon fulfillment of the provisions of the law, regulations, rules and procedures promulgated thereunder and subject to the following terms:

  

	 	a.	The approved program will be performed as detailed in your request within a period of 12 months – from 01/12/2009 and until 30/11/2010 (hereinafter: the
“Performance Period”). 

 Translation of 2010 Letter of Approval 

 

	 	b.	(1) You must inform the Office of the Chief Scientist about every change in the control of the recipient of the grant in the company’s shares and/or in one of the
following controlling means: (a) the right to vote in the company’s general meetings; (b) the right to appoint directors in the company; (c) the right to participate in the company’s profits. 

 

	 	 	(2) Transferring any percentage of the controlling means stated in subsection (1) to a non-Israeli resident or to a foreign company, which make the non-Israeli
resident or foreign company an interested party as defined in the Securities Law, 1968, requires notification to Office of the Chief Scientist and a written undertaking of the non-Israeli resident or the foreign company to the R&D Law.

  

	 	 	The letter of approval shall be signed in the form existing in the office of the Chief Scientist and in the website of the Ministry of Industry, Trade and Employment.

  

	 	c.	Additional terms: 

  

	 	 	Royalties shall be paid on income from all insulin pumps and accessories, spare parts, consumables, software, service. 

 

	 	d.	See the appendix in the matter of intellectual property. 

  

	 	e.	In the event of pledging the company’s assets to an Israeli bank against credit, the company must ensure that the pledge shall be subject to the R&D Law.

  

	 	f.	If the plan is connected to an agreement with an academic institution or an academic implementation company, the company must ensure that the agreement is subject to
the provisions of the R&D Law. 

  

			
	Sincerely,	 	
		
	 /s/ Eli Ofer
	 	
	Dr. Eli Ofer	 	
	The Chief Scientist	 	

 Attached: 
  

	 	1.	Budget breakdown appended to the letter of approval. 

  

	 	2.	Letter of commitment. 

  

	 	3.	Rules determined by the research committee for the performance of the provisions of the Law. 

 

	 	4.	Letter of approval intellectual property appendix. 

 Translation of 2010 Letter of Approval 

 
 [SUMMARY TRANSLATION] 

State of Israel 

Ministry of Trade and Industry 

Industrial Research and Development Administration 

Office of Chief Scientist/Office Controller 

28-4-2010 
 To: 

Nilimedix Ltd. 
 3 Ha’sadna 

Tirat Ha’Carmel 39032 

Budget Appendix with respect to Research and Development File Number 42678 

Appendix to Letter of Approval 

Subject to the letter of approval signed by the Chief Scientist from 28/04/2010 and following the decision of the research committee pursuant to Article
17(c) from 17/02/2010 with respect to research and development file which number is 42678 
 Subject of approved program: Advanced
Passive Insulin Pump 
 and performed by Nilimedix Ltd.  

Period of research: from 1/12/2009 until 30/11/2010 

The office’s budget commitment in an amount of up to NIS 2,392,151 is hereby approved for the performance of research and development
expenses for the approved program. 
  

			
	/s/	  	/s/
	  
	  	  

		
	Vice Chief Scientist	  	 Office controller, the Ministry of Industry,

Trade and Employment

 Translation of 2010 Letter of Approval 

 

 This page forms a part of the letter of approval 

Details of the budget for research and development in the matter of: advanced passive insulin pump 

Performance period from 1/12/2009 until 30/11/2010 

Budget page version 1.1 
 Request date

 Date of latest update 10/03/2010 
  

			
	File number:	 	 42678

	Preparation Date:	 	 10.03.2010

	Company	 	 Nilimedix

	Company Number	 	 5055

  

					
	 A. Human Resources
	  		  	
			
	Total amount human resources	  	 3,761,874
	  	
			
	B. Materials and consumable tools	  		  	
			
	Total Materials	  	 157,600
	  	
			
	C. Subcontractors	  		  	
			
	Total amount subcontractors in Israel	  	 1,530,000
	  	
			
	Total amount subcontractors abroad	  	 300,000
	  	
			
	Total amount subcontractors	  	 1,830,000
	  	
			
	D. Approved Equipment	  		  	
			
	Amount	  	 126,149
	  	
			
	E. Miscellaneous	  		  	
			
	Amount	  	 104,754
	  	
			
	Total in NIS	  	 5,980,378
	  	
			
	Grant 40%	  	 2,392,151
	  	

 Notes: 

A. The person performing the research shall be entitled to payments only with respect to expenses made and registered in a special account (including
registration of work hours of the researchers working in this research), and in accordance with the budget instructions of the Office of the Chief Scientist at the Ministry of Trade and Employment. 

B. This budget page is in effect only after signing the letter of approval 

 Translation of 2010 Letter of Approval 

 

 Signature: 
  

					
	/s/ David Lavi	  	/s/ Nilimedix Ltd.	  	13.04.2010
	  
	  	  
	  	  

			
	Office	  	Company	  	Date

 Translation of 2010 Letter of Approval 

 
 Nilimedix Ltd. 

number at the registrar of companies: 513229708 
  

			
	To	  	 Date: 16.03.10

	Industrial Research and Development Administration,	  	 Company 5055

	The Office of Chief Scientist	  	
	Ministry of Industry, Trade and Employment	  	
	5 Bank Israel, PO Box 3166	  	
	Jerusalem	  	

 Dear Sir, 

Re: Undertaking Letter and Notice about the Commencement of Performance of Approved R&D Plan 

Subject: Advanced Passive Insulin Pump 

File Number: 42678 
 We hereby inform
you that we commenced performing the approved plan, according to the referenced approval letter on 1.12.09. 
  

	 	1.	We declare and undertake to comply with all the provisions of the Law for the Encouragement of Research and Development in Industry 5744-1984 (hereinafter the
“Law”), and including: 

  

	 	a.	the obligation not to transfer to another the knowledge, the rights on the knowledge and the manufacturing rights deriving from the research and development without the
approval of the research committee. 

  

	 	b.	to pay royalties and file all reports according to the Law and the Regulations for the Encouragement of Research and Development in Industry (Rate of Royalties and
Rules for their Application), 5756-1996 (hereinafter the “Royalties Regulations”) and the procedures of the Industrial Research and Development Administration (hereinafter the “Administration”). 

 

	 	2.	We declare that we have read all instructions and procedures for financial reporting for R&D purposes and we will comply with them, including in connection with the
computerized system for the reporting on hours in assignment to tasks. 

  

	 	3.	We consent to the attribution of this file numbered: 42678 to plan 28035, subject Innovative Insulin Pump. 

 Translation of 2010 Letter of Approval 

 

	 	4.	Additional Undertakings: 

Royalties shall be paid on income from all insulin pumps and accessories, spare parts, consumables, software, service.

  

	 	5.	We hereby declare that we have separated and distinguished account/s in the framework of our financial bookkeeping for the purpose of performing this plan. The
recordings made in the account/s are direct, chronological, primary, systematic and only according to documentation. 

  

	 	6.	We hereby declare that we are aware that the referenced grant shall be paid subject to the terms of the approval and according to the Administration’s procedures.

  

	 	7.	The attached budget, including its details, terms and appendices constitutes a binding framework. Expenses deviating from this detailed framework will not be
recognized, unless under the approval of the Administration. 

  

	 	8.	Procedures: 

  

	 	a.	The company shall be entitled to advancement according to the procedures, provided that it has actually commenced performance of the plan. The advancement shall be
off-set from payments due according to the financial reports, excluding current advancement. 

  

	 	b.	Any additional payment shall be executed according to a detailed financial report which corresponds to the Administration’s procedures. Payment shall be made after
review of the aforesaid report. The grant’s recipient is obliged to file a financial report once every three months and a technical report at least once every half a year, and this on the Administration’s forms or in the same format.

  

	 	c.	The truthfulness of the financial report shall be confirmed by an authorized representative of the company, and documents witnessing actual payments to subcontractors
shall be attached, if such expense is reported. 

  

	 	d.	Any payment with respect to the approved grant shall be considered as advanced payment only until the approval of the final report. Until the final report, no more than
90% (including current advancement) shall be paid from the lower of the budgeted grant or the expense in the financial report. The remaining balance shall be paid only following receipt of a final financial report and a final technical report
together with confirmation from an accountant on behalf of the company. The payment shall be made following examination of the reports by representatives of the Administration. 

 Translation of 2010 Letter of Approval 

 

	 	e.	The company’s books of accounts, including the company’s balance sheets, shall be open for review of the Administration during a period of 7 years from the
commencement of performance of the approved plan, or 6 years from filing the final financial report, the later of the two. 

  

	 	f.	The Administration will have the right to setoff any sum due from the recipient of the support out of grant approved hereby. 

 

	 	g.	The grant’s recipient is not entitled to stop performing the plan without the prior written approval from the head of the Administration. If the plan is ceased
without such approval, the Administration may and shall be entitled to demand the return of the grant plus interest and linkage differentials in accordance with the law. 

 

	 	h.	The grant’s recipient is obligated to file a final financial report approved by an accountant on its behalf in a format acceptable to the Office of the Chief
Scientist and a final technical report to the approved plan, no later than 3 months from the date of completion of the approved plan. 

  

	 	i.	The Administration is entitled to demand additional technical reports at any time. 

 

	 	j.	An expense shall not be recognized unless the consideration therefor is paid, except overhead in salaries item. 

 

	 	k.	In the final financial report only expenses accumulated during the approved research period and paid no later than 60 days from its termination shall be recognized.

  

	 	l.	The Administration may demand interest and linkage differentials as provided by law on any sum due to it from the recipient of the grant. 

 

	 	9.	The abovementioned terms do not derogate from any statute and law applicable to the grant for this file. 

 

	 	10.	We hereby undertake to comply with intellectual property laws as shall be practiced in Israel from time to time, and we consent that if we are convicted for violation
of any of the intellectual property laws the Administration shall be entitled to retrospectively terminate any benefit granted by you, including grant, loan, benefit or any other financial advantage, or any part of such benefit, and demand their
repayment including interest and linkage differentials, according to the law. 

 Translation of 2010 Letter of Approval 

 

 Signature confirmation for the company 

The undersigned attorney Arik Kaufman hereby confirms that Nilimedix Ltd. is lawfully registered in Israel; that Efri Argaman and Amir Loberman who have
signed this agreement on its behalf, have signed it before me and are authorized to do so on its behalf; that their signature on this agreement binds the company. 
  

			
	 Date: 22.3.10
	 	       Signature and stamp: /s/ Arik Kaufman

  

							
	/s/	  	Amir Lobemran	  	CFO	  	Nilimedix
				
	/s/	  	Efri Argaman	  	CEO	  	
				
	  
	  	  
	  	  
	  	  

				
	Signature	  	Name	  	Position	  	Company’s stamp

 Translation of 2010 Letter of Approval 

 
 State of Israel 

Ministry of Trade and Industry 

Industrial Research and Development Administration 

Office of Chief Scientist 
  

	
	Jerusalem                     
	
	Letter of Approval Number: 42678
	(Fiscal regulation: 38020101)
	Group: 13

 To: 

Nilimedix Ltd. 
 3 Ha’sadna 

Tirat Ha’Carmel 39032 

Appendix to Letter of Approval 

Compliance with Intellectual Property Laws 

We have acknowledged your undertaking from
                     to comply with intellectual property laws as shall be practiced in Israel from time to time, that if you are convicted
for violation of the intellectual property laws of Israel, by a final and un-appealable judgment in an Israeli court, we shall be entitled to terminate any benefit granted to you by the Industrial Research and Development Administration, including
grant, loan, tax benefit or any other financial advantage, or any part of such benefit, and demand their return including interest and linkage differentials according to the law. 

 

	
	Sincerely,
	
	 /s/

	Dr. Eli Ofer
	The Chief ScientistAmendment, Consent and Forbearance Agreement

 Exhibit 10.1 

Execution Version 

AMENDMENT, CONSENT AND FORBEARANCE AGREEMENT 

THIS AMENDMENT, CONSENT AND FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is made and entered into on the 9th day
of July, 2010 (the “Effective Date”), by and among THERMO NO. 1 BE-01, LLC, a Delaware limited liability company (the “Company”), THE PRUDENTIAL INSURANCE COMPANY OF AMERICA, as Administrative Lender (the
“Administrative Lender”), THE PRUDENTIAL INSURANCE COMPANY OF AMERICA AND ZURICH AMERICAN INSURANCE COMPANY (the “Lenders”), DEUTSCHE BANK TRUST COMPANY AMERICAS, as Administrative Agent (the “Administrative
Agent”) and Collateral Agent (the “Collateral Agent”), and (for the limited purposes set out in Sections 4, 6, 8, 10, 11, 13 and 14 of this Forbearance Agreement) Raser Technologies, Inc. 

W I T N E S S E T H : 

WHEREAS, the Company, the Administrative Agent, the Lenders and the Administrative Agent are parties to that certain Credit Agreement
dated as of August 31, 2008 (as heretofore amended, the “Agreement”) entered into for the purpose of financing certain costs for the design, development, construction, installation, financing, testing, start-up and
commissioning of the Facility; 
 WHEREAS, prior to June 29, 2010 Raser performed the Availability Prove-Out and the
Capacity Prove-Out required by Sections 7.1 and 7.2 of the EPC Agreement; 
 WHEREAS, as a result of the Availability Prove-Out
and the Capacity Prove-Out described above, Facility Substantial Completion and Final Completion were not achieved which resulted, among other things, in a requirement that the Company pay the Obligations in full on June 30, 2010, which date
was the Guaranteed Final Completion Date prior to the amendment of that term pursuant to that certain Schedule Z Amendment dated as of June 30, 2010 (the “June 30 Amendment”); 

WHEREAS, as a result of the June 30 Amendment, the Guaranteed Final Completion Date has been extended to July 9, 2010;

 WHEREAS, on such extended Guaranteed Final Completion Date, a Credit Agreement Event of Default will occur and, as a result
thereof and in the absence of this Forbearance Agreement, the Company would be obligated pursuant to the Agreement to pay the Obligations in full, and the amount of the Obligations would exceed the aggregate amounts in the Development Account and
the other Security Accounts under the Account and Security Agreement; 
 WHEREAS, the Company has requested that the
Administrative Lender, the Administrative Agent and the Collateral Agent agree to the amendment of the Account and Security Agreement in order that (i) all funds (if any) in any Security Account, other than the Distribution Account, be
transferred to the Development Account on the Guaranteed Final Completion Date, (ii) the amount to be disbursed from the Development Account (after giving effect to the above-mentioned transfers thereto) on the Guaranteed Final Completion Date
and applied at such time to the Obligations will be only $27,000,000 rather than the full amount of the Obligations, and (iii) the funds remaining in the Development Account, after payment of such $27,000,000, and funds from time to time in the
Revenue Account, will be transferred to the O&M Account under the Account and Security Agreement and, subject to the terms and conditions of the Account and Security Agreement, used for the payment of approximately $450,000 of accrued accounts
payable and for the making of future payments for the operation, maintenance and preparation for sale of the Facility (including the payment of the expenses, including legal fees, of the Administrative Lender and the Agent) pending the sale of the
Facility, or the sale of the equity interests in the Company, as contemplated by this Forbearance Agreement; 

 WHEREAS, the Company desires that the Administrative Lender, the Administrative Agent and
the Collateral Agent (i) consent to the amendment of the Account and Security Agreement as described above, and (ii) waive compliance by the Company with certain Sections of the Agreement; 

WHEREAS, the Company desires that the Lenders, the Administrative Lender and the Administrative Agent forbear, subject to the terms and
provisions of this Forbearance Agreement, from exercising their rights and remedies (whether directly or through the Collateral Agent) with respect to the Credit Agreement Events of Default existing under the Agreement and described on Exhibit
A attached hereto (the “Specified Defaults”); 
 WHEREAS, the Administrative Lender has directed the
Administrative Agent and the Collateral Agent to enter into this Agreement; 
 WHEREAS, Raser is entering into this Forbearance
Agreement for the limited purposes set out herein; and 
 WHEREAS, the Company, the Lenders, the Administrative Lender, the
Administrative Agent and the Collateral Agent desire to amend the Agreement in certain respects as set forth herein. 
 NOW,
THEREFORE, in consideration of the agreements and covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

Section 1. Defined Terms. Any capitalized term used in this Forbearance Agreement but not otherwise defined in this
Forbearance Agreement shall have the meaning ascribed to such term in the Agreement, including by reference to Schedule Z. 

Section 2. Consent. Effective as of the Effective Date, the Administrative Lender hereby consents to the amendment of the
Account and Security Agreement, such amendment being dated as of the date hereof. The Administrative Lender hereby waives any claim that such action will constitute a Credit Agreement Event of Default , specifically including but not limited to a
Credit Agreement Event of Default under Section 7.3.1 of the Agreement arising from a failure to observe or the covenant in Section 6.16 of the Agreement. 

 

 -2- 

 Section 3. Waivers. Effective as of the Effective Date, the Administrative
Lender hereby waives compliance by the Company with Section 2.6.3 of the Agreement, the requirement in Section 5.1.1 of the Agreement that the audited financial statements of the Company not contain a “going concern” or like
qualification or exception, 5.1.5 of the Agreement, clauses (i) and (iv) of Section 5.1.11 of the Agreement, Section 5.2 of the Agreement, and Section 5.11 of the Agreement (but only if, not later than 14 days after the
Effective Date, the Company delivers to Prudential an operating plan and budget, in reasonable detail, covering the period from July 1, 2010 through June 30, 2011). 

Section 4. Forbearance. The Company and Raser acknowledge the existence of the Specified Defaults, including the failure of
Facility Substantial Completion and Final Completion to be achieved. Subject to the terms and conditions set forth herein, throughout the period commencing on the date of this Agreement and ending on June 29, 2011 (the
“Forbearance Period”), the Lenders, the Administrative Lender, the Administrative Agent and the Collateral Agent (acting at the written direction of the Administrative Lender) hereby agree to forbear from exercising any and all
available default rights and remedies under the Agreement, the Notes. the Account and Security Agreement, the deeds of trust creating the Liens described in Article XI of the Account and Security Agreement, the Class B
Investors Pledge Agreement and the Special Interest Investors Pledge Agreement and at applicable law as the result of the occurrence and continuance of the Specified Defaults. The Company and Raser acknowledge and agree that the foregoing
agreement to forbear exercising such default rights and remedies throughout the Forbearance Period shall not constitute a waiver of the Specified Defaults or a waiver of any other Credit Agreement Event of Default or Credit Agreement Default that is
not waived by Section 3 of this Forbearance Agreement, and that the Lenders, the Administrative Lender, the Administrative Agent and the Collateral Agent expressly reserve all such default rights and remedies. The Company and Raser further
acknowledge and agree that the Lenders, the Administrative Lender, the Administrative Agent and the Collateral Agent may exercise any and all such default rights and remedies at any time following the earliest to occur of (a) the expiration of
the Forbearance Period, (b) the occurrence during the Forbearance Period of any additional Credit Agreement Default or Credit Agreement Event of Default, other than those potential Credit Agreement Defaults or Credit Agreement Events of Default
expressly waived in Section 3 of this Forbearance Agreement (including, without limitation, any default under this Forbearance Agreement), or (c) any of MLE, Merrill Lynch, Pierce, Fenner & Smith Incorporated
(“MLP”), UTC, the Company, Raser or any of their respective Affiliates takes any action against the Facility, any other collateral for the Advances (including, without limitation, the additional collateral described in Article
XI of the Account and Security Agreement), the Company or Raser or any of its Affiliates which the Administrative Lender believes would materially adversely affect the interests of the Lenders, the Administrative Lender, the
Administrative Agent or the Collateral Agent (any of the events described in clause (a), (b) or (c), a “Forbearance Termination Event”). 
  

 -3- 

 Section 5. Modification of Certain Payment Obligations Under the Agreement Prior to
the Occurrence of a Forbearance Termination Event. Notwithstanding the provisions of Sections 2.3, 2.5,2.6.2, 2.8, 2.9, 6.10 and 6.20 of the Agreement, from and including the Effective Date until but not including the date of the occurrence of a
Forbearance Termination Event, (a) the aggregate respective principal amounts of the Advances to be repaid on the dates set out in the amortization schedule attached to the Agreement as Schedule 2.3 shall not be required to be repaid on
such dates, (b) interest on the Advances will accrue at the rate of 7% per annum and will be payable in kind on each Pre-Completion Interest Payment Date and on each Quarterly Transfer Date (if any) but will not be added to the respective
principal amounts of the Advances on which interest will accrue, (c) if a Change of Control occurs in connection with a Qualifying Sale (as defined in Section 6 below), the terms of Section 6 of this Forbearance Agreement, rather than
those of Section 2.6.2 or Section 6.20 of the Agreement, will govern the prepayment obligations of the Company as a result thereof, (d) if the Company sells all or substantially all its assets in a Qualifying Sale, the terms of
Section 6 of this Forbearance Agreement, rather than those of Section 6.10 of the Agreement, will govern, and (e) the terms of Section 6 of this Forbearance Agreement will govern the optional prepayment rights of the Company with
respect to the Advances. . From and after the occurrence of a Forbearance Termination Event, interest on the Advances will be payable in cash in Dollars, will accrue at the Default Rate and will be payable on demand. 

Section 6. Sale of the Facility or the Equity Interests in the Company. The Company and Raser hereby agree to use their
commercially reasonable best efforts to sell, not later than June 29, 2011, the Facility and the other collateral described in Article XI of the Account and Security Agreement as an entirety or, in the case of Raser, to use its
commercially reasonable best efforts to cause the Subsidiaries of Raser that are the owners of 100% of the Equity Interests in the Company to sell all such Equity Interests as an entirety; provided, that less than all the Facility and such
other collateral, or less than all such Equity Interests, may be sold in a transaction that otherwise qualifies as a Qualifying Sale (as defined below) so long as the Lenders receive a $6,000,000 cash payment and all other requirements of the fourth
sentence of this Section 6 are satisfied. Any such sale shall be solely for cash in Dollars and shall be made to a solvent Person that (a) is not an Affiliate of the Company, Raser, any Member in the Company, MLE, MLP, UTC or any other
Person involved in the operation or development of the Project, (b) is not described in Section 1603(g) of ARRA, or described as being ineligible to receive payments under Section 1603 of ARRA or under any guidance, terms and
conditions, frequently asked questions or other materials issued by the Department of the Treasury under Section 1603 of ARRA (“Treasury Guidance”), (c) has the requisite experience and resources to operate the Facility,
and (d) agrees to operate the Facility continuously as “specified energy property” as such term is defined in Section 1603(d) of ARRA, and under any Treasury Guidance, through at least March 31, 2014 (a sale to any such
Person meeting the foregoing requirements being a “Qualifying Sale”). Provided that no Forbearance Termination Event has occurred and is continuing at the time of any Qualifying Sale, the Lenders and the Administrative Agent agree
to instruct the Collateral Agent in writing at such time to release its Liens under the Financing Documents in respect of the Facility and the other collateral described in Article XI of the Account and Security Agreement, or in
respect of the Equity Interests in the Company, as the case may be (and any other collateral for the Obligations for which the Company has requested a lien release), against (x) payment in cash in Dollars to the Lenders of (i) 50% of the
Net Proceeds (as hereafter defined) and (ii) all expenses (including legal fees) of the Administrative Lender and the Agents, provided, that the aggregate amount payable pursuant to subclause (i) of this sentence shall not exceed
$6,000,000, and (y) delivery to the Lenders, the Administrative Lender and the Agents of a release which shall executed by the Company, Raser and all Members in the Company and must be acceptable to the Administrative Lender and the Agents (it
being understood that a release containing the terms, mutatis mutandis, of the release set out in Section 10 of this Forbearance Agreement shall be acceptable). Upon payment, at any time prior to the occurrence of a Forbearance
Termination Event and whether from the Net Proceeds of a Qualifying Sale as described above or from a cash payment from the Company or Raser, equal to $6,000,000 plus the expenses (including legal fees) of the Administrative Lender and the Agents
(and regardless of whether there has been a Qualifying Sale) and delivery of the releases, described in the preceding sentence, all obligations of the Company and Raser to the Administrative Agent, the Lenders and the Agents (other than those in
Article IX of the Agreement and any others that expressly survive repayment of the Obligations) shall be extinguished. As used in this Section 6, “Net Proceeds” shall mean the gross proceeds of the sale of the Project
and the other collateral described in Article XI of the Account and Security Agreement as an entirety, or the proceeds of the sale of all the Equity Interests in the Company as an entirety, as the case may be, less the normal and
customary costs of selling the foregoing (with brokerage commissions not to exceed 3% of the sales price and which may be payable only to Persons that are not Affiliates of the Company, Raser, any Member in the Company, MLE or any other Person
involved in the operation or development of the Project). Normal and customary closing costs shall consist of any legal and professional fees and, in the case of the sale of the Facility and the other collateral described in Article XI of the
Account and Security Agreement, premiums for a policy of owners’ title insurance but shall not include the payment of any Debt or of any obligation secured by a Lien against the asset being sold. The provisions of this Section 6 are
in consideration for the amendments, consents, waivers forbearances and other agreements under this Forbearance Agreement, and such provisions shall not be deemed to create a joint venture, partnership or other joint ownership arrangement or
relationship between the Lenders (including the Administrative Lender) and the Agents, on the one hand, and the Company, Raser and the Members in the Company on the other hand, and in no event do the parties intend, and in no event shall such
provisions or any other portion of this Forbearance Agreement or any other Transaction Document be construed, to be an agreement by the Lenders (including the Administrative Lender) or the Agents to share in any operating or other losses or costs
incurred by the Company, Raser or the Members in the Company or to be responsible, in any manner or to any extent, for any liabilities of the Company, Raser or the Members of the Company to any third party. 

 

 -4- 

 Section 7. Amendments to the Agreement. Effective as of the Effective Date, the
Agreement is hereby amended as set forth below: 
 (a) Amendment to Section 2.5. Section 2.5 of
the Agreement is hereby amended by deleting the first sentence thereof and by deleting “, at any time and from time to time on or after the seventh (7th) anniversary of the Facility Substantial Completion Date,” from the second
sentence thereof. 
 (b) Amendment to Section 2.6.4. Section 2.6.4 of the Agreement is hereby
deleted and replaced with “[RESERVED]”. 
 (c) Amendment to Section 2.6.5.
Section 2.6.5 of the Agreement is hereby amended and restated in its entirety to read as follows: 
 Mandatory
Prepayment. The Company, the Lenders and the Administrative Lender acknowledge and agree that, in the absence of the Amendment, Consent and Forbearance Agreement dated as of July 9, 2010, by and among the Company, the Lenders, the
Administrative Agent, the Collateral Agent and Raser (as from time to time amended, the “Forbearance Agreement”), the full amount of the Obligations (including the outstanding principal amount of the Advances, accrued interest
thereon and the Make-Whole Amount with respect to such principal amount) would be due and payable on the Guaranteed Final Completion Date and that the full amount of the Obligations exceeds the aggregate amount in the Development Account and the
other Security Accounts under the Account and Security Agreement. As a result of the Forbearance Agreement, the Company instead shall be required on the Guaranteed Final Completion Date to pay only Obligations in the aggregate amount of
$27,000,000, which amount is intended by the parties to be disbursed pursuant to Section 3.9.3.1 of the Account and Security Agreement on the Guaranteed Final Completion Date. Notwithstanding the second sentence of
Section 2.11.7, such $27,000,000 shall be applied by the Lenders to $19,916,332.51 principal amount of the Advances, $51,964.10 of accrued interest on the Advances from June 30, 2010 to the Guaranteed Final Completion Date and the
$7,031,703.39 of Make-Whole Amount with respect to such principal amount. The remaining $9,777,440.42 principal amount of the Advances shall continue to constitute an Obligation and shall bear interest and be payable as provided in this Agreement
and in Section 5 of the Forbearance Agreement. 
  

 -5- 

 (d) Amendment to Section 5.1. Section 5.1 of the Agreement
is hereby amended by adding a new Section 5.1.12, which shall read as follows: 
 Reports Under ARRA and Reports
Concerning Sale Efforts. Promptly, and in any event prior to ten Business Days before any such report would be delinquent under the American Recovery and Reinvestment Act of 2009, as amended from time to time, and the regulations issued
thereunder (“ARRA”), or under any guidance, terms and conditions, frequently asked questions or other materials issued by the Department of Treasury under Section 1603 of ARRA (“Treasury Guidance”), a copy of
each report required to be filed by the Company or with respect to the Project, including the annual report required by Section 5 of the Terms and Conditions for payments described in Section 1603 of ARRA currently available at
http://www.ustreas.gov/recovery/1603.shtml. In addition, the Company shall provide to the Administrative Lender, no less frequently than monthly, information in reasonable detail regarding the efforts being made by the Company to sell the
Facility, or by Raser and certain of its Subsidiaries to sell the Equity Interests in the Company, as required by Section 6 of the Forbearance Agreement. 

(e) Amendment to Section 5.9. Section 5.9 of the Agreement is hereby amended by adding a new
Section 5.9.4, which shall read as follows: 
 maintain and operate the Facility, or cause the Facility to be
maintained and operated, so that at all times the Facility shall constitute “specified energy property” as such term is defined under Section 1603(d) of ARRA and under any Treasury Guidance. 

 

 -6- 

 (f) Amendment to Section 6.3. Section 6.3 of the Agreement
is hereby amended by amending clause (b) thereof in its entirety to read as follows: 
 (b) the Company may make payments
not in excess of $50,000 per month, as payments to Raser under the O&M Agreement. for the salaries and related costs of personnel who are involved in the efforts of the Company and Raser to consummate a Qualifying Sale as such term is
defined in Section 6 of the Forbearance Agreement, 
 (g) Amendment to Section 6.21.
Section 6.21 of the Agreement is hereby amended by revising the introductory clause thereof to read as follows: 
 Other
than as expressly provided for in Article XI of the Account and Security Agreement with respect to additional collateral described therein and in Section 6 of the Forbearance Agreement, 

(h) Amendment to Article VI. Article VI of the Agreement is hereby amended by inserting the following immediately
after Section 6.23 thereof: 
 Section 6.24. Limitations on Capital Expenditures. The Company will not directly
or indirectly make any capital expenditure with respect to the Project except those required for the maintenance of the Facility. 

(i) Amendment to Article VII. Article VII of the Agreement is hereby amended by adding the following immediately
after Section 7.16 thereof: 
 Section 7.17 Breach of Forbearance Agreement. The Company or Raser shall fail to
observe or perform any covenant, condition or agreement contained in the Forbearance Agreement. 
 (j)
Amendments to Section 15.4.1. Section 15.4.1 of the Agreement is hereby amended by (i) inserting the word “Agent” immediately after the word “Collateral” in the second line thereof, (ii) deleting
“(a)” in the third line thereof, (iii) inserting a period after the parenthesis in the sixth line thereof, and (iv) deleting the remainder of such Section. 

(k) Amendment to Section 16.9. Section 16.9 of the Agreement is hereby amended by inserting the following
at the end of such Section: 
 Notwithstanding the foregoing, nothing in this Section 16.9 or any other provision of any
other Transaction Document shall limit the obligations of, or the recourse of the Agents or the Lenders against, Raser in respect of its obligations under the Forbearance Agreement (it being understood and agreed that the Forbearance Agreement does
not create additional obligations of Raser under any of the Transaction Documents). 
  

 -7- 

 Section 8. Representations and Warranties. In order to induce the Administrative
Lender and the Agents to enter into this Forbearance Agreement, each of the Company and Raser represents and warrants (as to itself) that the following statements are true and correct as of the Effective Date: 

(a) Organization; Powers. Each of the Company and Raser is duly organized, validly existing and in good standing
under the laws of the State of Delaware and has all requisite limited liability company or corporate power and authority to carry on its business as such business is now conducted, and as proposed to be conducted. 

(b) Authority; Enforceability. The transactions contemplated hereby and by the amendment to the Account and
Security Agreement described in Section 2 are within the Company’s or Raser’s limited liability company or corporate powers and have been duly authorized by all necessary limited liability company or corporate action. This
Forbearance Agreement and such amendment have been duly executed and delivered by the Company or Raser and constitute legal, valid and binding obligations of the Company or Raser, enforceable in accordance with their respective terms except as such
terms may be limited by (i) Bankruptcy, insolvency or similar laws affecting creditors’ rights generally, or (ii) general principles of equity, whether considered in a proceeding in equity or at law. 

(c) Approvals; No Conflicts. The transactions contemplated hereby and by the amendment to the Account and
Security Agreement described in Section 2: (i) do not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any other third Person, nor is any such consent, approval,
registration, filing or other action necessary for the validity or enforceability of this Forbearance Agreement, any of such other documents or the consummation of the transactions contemplated hereby or thereby, except such as have been obtained or
made and are in full force and effect or are not yet required to be obtained; (ii) will not violate any Applicable Law or regulation or the Organizational Documents of the Company or Raser or any order of any Governmental Authority;
(iii) will not violate or result in a default under any indenture, agreement or other instrument binding upon the Company, Raser or any of their respective Properties, or give rise to a right thereunder to require any payment to be made by the
Company or Raser; and (iv) will not result in the creation or imposition of any Lien on any Property of the Company (other than the Liens created by the Financing Documents) or Raser. 

(d) Litigation. There are no claims, actions, suits, investigations or proceedings (including any arbitration
proceeding) of any nature, at law or in equity, pending or, to the knowledge of the Company and Raser, threatened by or against the Company, Raser or any of their respective Affiliates which would materially adversely affect the Company’s or
Raser’s ability to execute, deliver and perform under this Forbearance Agreement, the Agreement or the amendment to the Account and Security Agreement described in Section 2 and to consummate the transactions contemplated hereby or
thereby. 
  

 -8- 

 (e) Defaults. There is no Credit Agreement Event of Default
outstanding other than the Specified Defaults. 
 (f) Totality of Agreements. The only agreements between
the Company, Raser, IRP or any of their Affiliates, on the one hand, and MLE, MLP and any of their respective Affiliates, on the other hand, that relate to the redemption of the Class A Interests or the Redemption Note, the Raser Guaranty or
Raser Note are the documents described in the Agreement. 
 Section 9. Conditions Precedent. The parties hereto
agree that this Forbearance Agreement and the consent, waiver and amendments to the Agreement contained herein shall become effective upon the satisfaction of each of the following conditions: 

(a) Execution and Delivery of this Forbearance Agreement. The Administrative Lender and each Agent shall have
received a copy of this Forbearance Agreement executed and delivered by the Company and Raser. 
 (b)
Resolutions. The Administrative Lender shall have received a certificate of (i) the secretary of IRP setting forth resolutions of its managers with respect to the authorization of this Forbearance Agreement and the amendment of the
Account and Security Agreement described in Section 2, and (ii) the secretary or an assistant secretary or Raser setting forth resolutions of its board of directors with respect to the authorization of this Forbearance Agreement.

 (c) Other Documents. The Administrative Lender and each Agent shall have received fully executed copies
of the amendment of the Account and Security Agreement described in Section 2 (which shall be in form, scope and substance satisfactory to the Administrative Lender). 

(d) Payment of Reduced Prepayment Amount. Simultaneously with the execution and delivery of this Forbearance
Agreement, the Lenders shall have received the $27,000,000 required to be disbursed from the Development Account as contemplated by Section 2.6.5 of the Agreement, as amended hereby. 

(e) Payment of Costs, Expenses, Etc. The Company shall have paid all costs and expenses of the Agents and the
Administrative Lender in connection with the preparation, reproduction, execution and delivery of this Forbearance Agreement and the other instruments and documents to be delivered hereunder (including the fees and expenses of counsel for the Agents
and the Administrative Lender). In addition, the Company shall have paid any and all stamp or other taxes, recordation fees and other fees payable in connection with the execution, delivery, filing or recording of this Forbearance Agreement and the
other instruments and documents to be delivered hereunder, and the Company agrees to hold the Agents and the Lenders harmless from and against any and all liabilities with respect to or resulting from any delay or omission in paying such taxes or
fees. 
  

 -9- 

 Section 10. RELEASE. IN CONSIDERATION OF THE LENDERS AND THE
AGENTS ENTERING INTO THIS AGREEMENT, THE COMPANY AND RASER HEREBY ACKNOWLEDGE THAT THEIR OBLIGATIONS UNDER THE AGREEMENT, THIS FORBEARANCE AGREEMENT AND EACH OTHER FINANCING DOCUMENT EXECUTED IN CONNECTION THEREWITH OR HEREWITH ARE ABSOLUTE AND
UNCONDITIONAL WITHOUT ANY RIGHT OF RESCISSION, SETOFF, COUNTERCLAIM, DEFENSE, OFFSET, CLAIM OR DEMAND OF ANY KIND OR NATURE WHATSOEVER THAT CAN BE ASSERTED TO REDUCE OR ELIMINATE ALL OR ANY PART OF THE COMPANY’S LIABILITY TO REPAY THE
OBLIGATIONS UNDER THE AGREEMENT, THIS FORBEARANCE AGREEMENT AND EACH OTHER FINANCING DOCUMENT EXECUTED IN CONNECTION THEREWITH OR HEREWITH OR TO SEEK AFFIRMATIVE RELIEF OR DAMAGES OF ANY KIND OR NATURE FROM ANY RELEASED PARTY (AS DEFINED BELOW). THE
COMPANY AND RASER HEREBY VOLUNTARILY AND KNOWINGLY RELEASE AND FOREVER DISCHARGE THE LENDERS, THE ADMINISTRATIVE LENDER AND THE AGENTS AND EACH OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES, COUNSEL, AGENTS, ATTORNEYS-IN-FACT,
SUCCESSORS, AND ASSIGNS (COLLECTIVELY, THE “RELEASED PARTIES”), FROM ALL POSSIBLE CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, DAMAGES, COSTS, EXPENSES, AND LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN, ANTICIPATED OR UNANTICIPATED, SUSPECTED
OR UNSUSPECTED, FIXED, CONTINGENT, OR CONDITIONAL, AT LAW OR IN EQUITY, ORIGINATING IN WHOLE OR IN PART ON OR BEFORE THE DATE THIS FORBEARANCE AGREEMENT IS EXECUTED, WHICH THE COMPANY OR RASER MAY NOW OR HEREAFTER HAVE AGAINST THE RELEASED PARTIES,
IF ANY, AND IRRESPECTIVE OF WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR REGULATIONS, OR OTHERWISE, AND ARISING OUT OF OR IN CONNECTION WITH OR BY REASON OF THE AGREEMENT, THIS FORBEARANCE AGREEMENT OR ANY OTHER FINANCING
DOCUMENT EXECUTED IN CONNECTION THEREWITH OR HEREWITH, INCLUDING, WITHOUT LIMITATION, THE EXERCISE OF ANY RIGHTS AND REMEDIES UNDER THE AGREEMENT, THIS FORBEARANCE AGREEMENT AND ANY OTHER FINANCING DOCUMENT EXECUTED IN CONNECTION THEREWITH OR
HEREWITH, AND THE NEGOTIATION FOR AND EXECUTION OF THE AGREEMENT, THIS FORBEARANCE AGREEMENT AND THE DOCUMENTS EXECUTED IN CONNECTION THEREWITH AND HEREWITH (BUT EXCLUDING IN ALL CASES ANY OF THE FOREGOING ARISING FROM THE GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT OF THE RELEASED PARTIES). THE RELEASES AND WAIVERS CONTAINED IN THIS SECTION 10 ARE GIVEN AND MADE BY THE COMPANY AND RASER WITH THEIR FULL KNOWLEDGE AND UNDERSTANDING OF THE CIRCUMSTANCES AND EFFECT THEREOF AND AFTER THEIR HAVING
CONSULTED LEGAL COUNSEL WITH RESPECT THERETO. 
  

 -10- 

 Section 11. Limited Nature of Forbearance; Effect on Agreement and Other Transaction
Documents; Confirmation. The forbearance by the Lenders and the Agents described herein shall be effective as of the Effective Date and is limited to the Specified Defaults. This forbearance is limited to the extent described herein and
shall not be construed to be a consent to or a waiver of the Specified Defaults or, except as otherwise expressly provided in Section 3, any other terms, provisions, covenants, warranties or agreements contained in this Forbearance Agreement,
the Agreement or in any of the other Transaction Documents. The Lenders, the Administrative Lender and the Agents reserve the right to exercise any available rights and remedies in connection with any other present or future Credit Agreement
Defaults and Credit Agreement Events of Default. The Company and Raser hereby further agree and acknowledge that (i) the Specified Defaults have not been waived as a result of this Forbearance Agreement and that such forbearance is temporary in
nature, and (ii) concurrently with the Forbearance Termination Date, all rights and remedies that the Lenders and the Agents have agreed not to exercise as a result of Section 4 of this Forbearance Agreement shall be automatically
reinstated. The execution, delivery and effectiveness of this Forbearance Agreement shall not operate as a waiver of any right, power or remedy under this Forbearance Agreement, the Agreement or any other Transaction Document. Without limiting the
generality of the foregoing, nothing in this Forbearance Agreement shall be deemed (A) to constitute a waiver of compliance or consent to noncompliance by the Company, Raser or any other Person with respect to any term, provision, covenant or
condition of this Forbearance Agreement, the Agreement or any other Transaction Document; (B) to prejudice any right or remedy that any Lender or Agent may now have or may have in the future under or in connection with this Forbearance
Agreement, the Agreement or any other Transaction Document; or (C) to constitute a waiver of compliance or consent to noncompliance by the Company, Raser or any other Person with respect to the terms, provisions, covenants and conditions
described herein. Except as specifically modified by this Forbearance Agreement, the terms and provisions of the Agreement are hereby ratified and confirmed and remain in full force and effect. The consents, forbearance and waivers contained herein
shall be limited precisely as written and shall relate solely to the Agreement and the Financing Documents in the manner and to the extent described herein, and nothing in this Forbearance Agreement shall be deemed (a) to constitute a waiver
of, or deviation from, compliance by the Company, Raser or any other Person with respect to any other term, provision or condition of this Forbearance Agreement, the Agreement or any other Transaction Document or with respect to any other
transaction or matter, or (b) to prejudice any right or remedy that any Agent or Lender (including the Administrative Lender) may now have, or may have in the future, under or in connection with this Forbearance Agreement, the Agreement or any
other Transaction Document. 
 Section 12. Governing Law. This Forbearance Agreement shall be governed by and
construed in accordance with the laws of the State of New York, excluding any conflicts of law rule or principle that might refer the governance or construction of this Forbearance Agreement to the law of another jurisdiction. Each party hereby
irrevocably submits to the jurisdiction of the courts of the State of New York in the County of New York or of the United States of America in the Southern District of New York and hereby waives, to the fullest extent permitted by law, any objection
that it may now or hereafter have to the laying of venue in an such action or proceeding in any such court. 
 Section 13.
Further Assurances. In connection with this Forbearance Agreement and the transactions contemplated hereby, upon the request of the Administrative Lender and at the expense of the Company the parties hereto agree to execute and deliver any
additional documents and instruments and perform any additional acts that may be reasonably required or useful to carry out the intent and purpose of this Forbearance Agreement and as are not inconsistent with the terms hereof. 

 

 -11- 

 Section 14. Public Announcements. The parties hereto shall consult with one
another before issuing any public announcement, statement or other disclosure with respect to this Forbearance Agreement or the matters contemplated hereby and no party shall issue any such public announcement, statement or other disclosure without
the prior written consent of the other parties (which consent shall not be unreasonably withheld or delayed) unless such action is required by Applicable Law. Each party, upon the request of any other party, shall provide to such other party, and
such other party shall have the right to review in advance all information relating to this Forbearance Agreement or the matters contemplated hereby that appear in any filing made in connection with the transactions contemplated hereby. 

Section 15. Counterparts. This Forbearance Agreement may be executed in any number of counterparts, each of which shall be an
original but all of which together will constitute one instrument, binding upon all parties hereto, notwithstanding that all of such parties may not have executed the same counterpart. 

Section 16. Joint Efforts. To the full extent permitted by Applicable Law, neither this Forbearance Agreement nor any
ambiguity or uncertainty in this Forbearance Agreement will be construed against any of the parties hereto, whether under any rule of construction or otherwise. On the contrary, this Forbearance Agreement has been prepared by the joint efforts of
the respective attorneys for, and has been reviewed by, each of the parties hereto. 
 Section 17. Authorization of
Collateral Agent. The Administrative Lender (with the consent of the Lenders) hereby directs the Collateral Agent to enter into this Forbearance Agreement and the amendment to the Account and Security Agreement contemplated by Section 2
hereof. 
 [Signatures on Next Page] 
  

 -12- 

 IN WITNESS WHEREOF, each party has caused this Amendment, Consent and Forbearance
Agreement to be signed on its behalf as of the date first written above (with this Amendment, Consent and Forbearance Agreement being executed by Raser only for the limited purposes set out in herein). 

 

							
	THERMO NO. 1 BE-01, LLC,	 	
	a Delaware limited liability company	 	
			
	By:	 	Intermountain Renewable Power, LLC	 	
	Its:	 	Managing Member	 	
				
		 	By:	 	 /s/ Richard D. Clayton
	 	
		 	Name:	 	Richard D. Clayton	 	
		 	Title:	 	Manager	 	
		
	 RASER TECHNOLOGIES, INC., a Delaware corporation,

as Contractor and indirect owner of the Equity Interests in the Company
	 	
			
	By:	 	 /s/ Richard D. Clayton
	 	
	Name:	 	Richard D. Clayton	 	
	Title:	 		 	
		
	 THE PRUDENTIAL INSURANCE COMPANY OF AMERICA,

as Administrative Lender
	 	
			
	By:	 	 /s/ Ric E. Abel
	 	
	Name:	 	Ric E. Abel	 	
	Title:	 	Vice President	 	
		
	 THE PRUDENTIAL INSURANCE COMPANY OF AMERICA,

as a Lender
	 	
			
	By:	 	 /s/ Ric E. Abel
	 	
	Name:	 	Ric E. Abel	 	
	Title:	 	Vice President	 	
		
	ZURICH AMERICAN INSURANCE COMPANY	 	
			
	By:	 	Prudential Private Placement Investors, L.P.,	 	
		 	(as Investment Advisor)	 	
			
	By:	 	Prudential Private Placement Investors, Inc.	 	
		 	(as its General Partner)	 	
				
		 	By:	 	 /s/ Ric E. Abel
	 	
		 		 	Vice President	 	

			
	 DEUTSCHE BANK TRUST COMPANY AMERICAS,

as Administrative Agent and Collateral Agent

		
	By:	 	 /s/ Yana Kislenko

	Name:	 	Yana Kislenko
	Title:	 	Assistant Vice President
		
	By:	 	 /s/ Randy Kahn

	Name:	 	Randy Kahn
	Title:	 	Vice President

 EXHIBIT A 

Specified Defaults 
 Any
Credit Agreement Event of Default existing on the Effective Date due to the Facility Substantial Completion Date or Final Completion not having occurred before the Guaranteed Final Completion Date 

The Credit Agreement Events of Default in existence on the Effective Date due to the failure of the Company to deliver the reports required by
Section 5.1.4 of the Agreement, the Annual Operating Plan and Budget required by Section 11 of the Agreement and the notices required by Section 5.19 of the Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]